Alnylam pharmaceuticals reports first quarter 2022 financial results and highlights recent period activity

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today reported its consolidated financial results for the first quarter ended march 31, 2022 and reviewed recent business highlights. “the first quarter of 2022 saw a steady increase in patients on therapy across all products in our commercial portfolio, despite combined product revenues that were down compared to q4 2021, as anticipated, given several non-recurring revenue be
ALNY Ratings Summary
ALNY Quant Ranking